Treatment with ISIS @ resulted in dose-dependent and prolonged decreases in plasma APOC@ levels when the drug was administered as a single agent ( decreases of @ % in the @-mg group , @ % in the @-mg group , and @ % in the @-mg group , vs. an increase of @ % in the placebo group ) and when it was administered as an add-on to fibrates ( decreases of @ % in the @-mg group and @ % in the @-mg group , vs. a decrease of @ % in the placebo group ) .